Podcasts about AAV

More trade targets...this Detroit Red Wings podcast breaks down Red Wings trade possibilities other than Petterson - from Matt Barzal to Mason McTavish and beyond. News and analysis digs into Steve Yzerman's middle-tier trade targets, Stanley Cup Final Game 1, NHL All-Star changes, and two prospect profiles ahead of the draft. (00:00) - Intro (04:05) - Matt Barzal Trade Talk Barzal's market is reportedly being explored - what the Islanders would want, why his speed and term make sense for Detroit, and whether the acquisition cost is even close to reasonable. (18:55) - Mason McTavish and Shane Wright A reclamation project breakdown on McTavish coming off a missed camp and contract dispute, plus whether Shane Wright's pedigree is inflating his price in Seattle. Kent Johnson sneaks into the conversation too. (34:05) - Samoskevich and Vincent Trocheck Samoskevich as an RFA offer sheet wildcard out of Florida and why Trocheck's age makes the Rangers asking price tough to stomach, even with the cap-friendly AAV. (41:40) - Stanley Cup Final Game 1 A nine-goal shootout in Carolina with Tomas Hertl burying the winner for Vegas. Mitch Marner enters the Conn Smythe conversation and Nikolaj Ehlers makes his case too. (46:30) - All-Star Game Changes Country vs. country 3-on-3 format returns, the skills competition gets a 25-and-under cap with a $1M prize, and how the league could actually make it watchable. (51:35) - Prospect Profile: Caleb Malhotra Manny's kid headed to Vancouver? The pro-style center, the Brantford context, and whether his floor justifies a top-five pick. (59:20) - Prospect Profile: Alexander Bilecki The Memorial Cup champion Kitchener defenseman as a possible fit at pick 47, with an Albert Johansson comparison baked in. (1:06:10) - Overtime Patron questions on Mavrik Bourque as a 2C solution, the early vs. late birthday draft factor, Jaccob Slavin envy, and more. --- This episode is brought to you by Hims. Visit hims.com/wingedwheel for your personalized hair loss treatment options. Support the show: Patreon.com/WingedWheelPodcast Head over to wingedwheelpodcast.com to find all the ways to listen, how to support the show, and so much more!

It's time - this Detroit Red Wings podcast breaks down the 2026 NHL Draft strategy for Steve Yzerman with no first-round pick in hand. News and analysis covers Yzerman's free agency options, prospect profiles, Stanley Cup playoff updates, and a coaching shakeup in Toronto. (00:00) - Intro Free agency is looking THIN. (04:25) - 2026 Draft Strategy With no first-round pick after the Justin Faulk trade, what should Kris Draper and the Red Wings do? The case for swinging for the fences and avoiding the safer Brady Cleveland/Andrew Gibson archetype that's burned them in the past, and how they can get a Stankoven or Hutson of their own. (13:25) - Trading Up in the Draft Is moving up worth the cost? Why Sebastian Cossa probably isn't getting it done on his own, and why the 33-38 range could be the sweet spot for catching fallers. (40:35) - Prospect Profile: Gavin McKenna Sick puck skills, Kucherov-level vision, and questions about his off-puck effort. Why he's still the favorite to go first overall over Stenberg. (49:45) - Prospect Profile: Victor Plante Max Plante's brother and what he could bring as a potential second-round target. (56:30) - Stanley Cup Playoff Updates Charlie McAvoy's suspension, the diving problem, and Carolina sitting back watching Montreal and Buffalo beat each other up. (1:02:45) - NHL news: Berube Fired by Toronto; Cassidy in Demand Why the move had to happen and what kind of coach the Leafs need next. Vegas blocking interview requests and Edmonton's never-ending dysfunction. (1:11:05) - Charlie Coyle Contract Six years, $6 million AAV, full no-move through age 38 - what does this mean for this year's July 1st market?> (1:19:55) - Overtime Questions Your questions on Kyrou, Brady Tkachuk rumors, Mackie Samoskevich, and more. --- This episode is brought to you by Hims. Visit hims.com/wingedwheel for your personalized hair loss treatment options. Support the show: Patreon.com/WingedWheelPodcast Head over to wingedwheelpodcast.com to find all the ways to listen, how to support the show, and so much more!

Marty Makary's hold on the top job at FDA is slipping, with White House leaks about President Donald Trump's displeasure with the FDA commissioner shifting the question from whether he will be fired to when. On the latest BioCentury This Week podcast, Washington Editor Steve Usdin discusses the pressures on Makary, how long he will hold onto his post, and the leading candidates to succeed him.BioCentury's analysts then discuss solutions to AAV's redosing problem, which could reignite industry interest in a modality that has fallen out of favor, and other topics in the spotlight at this week's American Society of Gene and Cell Therapy annual meeting. The analysts also discuss opportunities to attend and present academic posters at the third BioCentury Grand Rounds U.S. conference June 3-5 in Seattle. This episode of the BioCentury This Week podcast has been brought to you by Jeito Capital.View full story: https://www.biocentury.com/article/659426#FDA #GeneTherapy #AAV #CellTherapy #Biopharma00:01 - Sponsor Message: Jeito Capital01:43 - Bio€quity Europe Prague Highlights04:54 - Makary on Thin Ice14:37 - Grand Rounds Poster Pitch16:40 - AAVs at ASGCTTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of dynamic changes and strategic shifts reshaping these industries, driven by scientific advancements and regulatory updates. Let's start with Biogen, which recently resolved an investor lawsuit concerning its Alzheimer's drug, Aduhelm. Approved under controversial circumstances by the FDA, Aduhelm faced scrutiny for its efficacy and costs. This settlement is a critical reminder of the importance of transparent communication with investors, especially when navigating high-stakes therapeutic areas like Alzheimer's. The broader implication for pharmaceutical companies is the need to balance innovation with accountability and transparency—a challenge that resonates across the industry. Meanwhile, Pfizer's decision to vacate office space in South San Francisco exemplifies a significant trend toward remote work, accelerated by the COVID-19 pandemic. This shift suggests that traditional workplace models are being reassessed in favor of flexibility and cost efficiency, a change likely to influence real estate investments and organizational structures across biotech firms. Amgen stands out with its notable financial growth highlighted by CEO Robert Bradway's $24.7 million compensation package in 2025. This success underscores Amgen's strategic prowess in maintaining robust performance amidst competitive pressures. Their approach could serve as a blueprint for other firms aiming to achieve sustained growth through innovation and strategic management. On the clinical trial front, Insmed's decision to halt development of Brinsupri after underwhelming mid-stage results illustrates the inherent risks in drug development. This highlights the need for rigorous trial designs and adaptive strategies within development pipelines to address potential setbacks efficiently. Turning to Gilead Sciences, there's a strategic pivot from mergers and acquisitions towards strengthening its internal research pipeline, now described as stronger than ever. This shift away from external acquisitions reflects an industry trend prioritizing internal R&D capabilities, potentially leading to breakthrough therapies that enhance patient care while ensuring sustained business growth. In regulatory developments, GSK's Exdensur received new approval in China, showcasing the ongoing globalization of pharmaceutical markets. Navigating diverse regulatory environments becomes crucial for maximizing drug accessibility worldwide. Another trend is seen through Invivyd's “Antibodies for Any Body” campaign featuring Olympic skier Lindsey Vonn. Leveraging public figures can significantly raise awareness about innovative treatments, playing a crucial role in educating the public about medical advancements. There's also significant financial movement within the sector as Jeito Capital announced a record $1.2 billion fundraising for an independent biopharma-focused European fund. This capital influx is poised to accelerate research and development activities across Europe, potentially leading to new therapeutic breakthroughs. Vivtex Therapeutics' $2.1 billion deal with Novo Nordisk illustrates the power of strategic collaborations in advancing therapeutic solutions and enhancing drug delivery systems—key components for improving patient outcomes. Sidewinder Therapeutics is making strides with a $137 million funding round to develop antibody-drug conjugates (ADCs), highlighting investor confidence in technologies that integrate precision medicine approaches to offer potent cancer treatments with reduced side effects. Astellas Pharma's collaboration with Dyno Therapeutics marks another milestone in gene therapy advancements. A $15 million agreement aims at utilizing engineered adeno-associated virus (AAV) capsids for muscle disorders, proSupport the show

Another March Sadness episode. This Detroit Red Wings podcast covers the Red Wings vs Senators crushing loss in what should have been their most winnable big game of the season. Hockeytown news and analysis breaks down where the playoff race stands, Larkin's return, and Yzerman extending JBD. (00:55) - Intro (03:30) - Ottawa Loss Breakdown Red Wings fall to injury-depleted Senators on back-to-back despite Ottawa missing five defensemen including Jake Sanderson. Discussion on the Patrick Kane offside that negated an Alex DeBrincat goal, plus how Dylan Larkin's return, Yakemchuk's guaranteed goal, and DeBrincat and Zub's fight all ended in disappointment for Todd McLellan's squad. (27:45) - Playoff Race Math Breaking down where Detroit sits after the regulation loss and which teams they need to leapfrog with limited games remaining - can Steve Yzerman's roster do it? How much can Moritz Seider and Simon Edvinsson support from the back end for a stagnant offense? (38:20) - Jacob Bernard-Docker Extension Steve Yzerman extends JBD to a 2 year, $1.6 million AAV extension - what this means for the blue line depth, Axel Sandin-Pellikka, and future moves. (46:00) - Axel Sandin Pellikka Sent Down ASP returns to Grand Rapids Griffins before the Ottawa game - how is his path affected? (53:40) - NHL Suspension Debate Around the league discipline decisions and how stars like Connor McDavid may affect future changes with George Parros and Gary Bettman. (1:05:00) - Overtime Q&A Your questions on the March sadness in Hockeytown and whether it's truly over for the Red Wings' playoff hopes. --- Jessi Pierce Family Fundraiser: https://www.gofundme.com/f/support-mike-hinrichs-after-losing-jessi-pierce-children This episode is brought to you by Hims. Visit hims.com/wingedwheel for your personalized hair loss treatment options. Support the show: Patreon.com/WingedWheelPodcast Head over to wingedwheelpodcast.com to find all the ways to listen, how to support the show, and so much more!

RNA binding proteins help cells control how genetic information becomes working proteins, and Gene Yeo, Ph.D., M.B.A., at UC San Diego investigates how their disruption contributes to neurodegenerative disease. Yeo focuses on ALS, a severe motor neuron disease in which the RNA binding protein TDP-43 moves from the nucleus to the cytoplasm, loses normal RNA processing functions, and triggers cryptic exons that damage key neuronal genes, including one linked to motor neuropathy. His group maps these RNA changes and develops small nuclear RNA guides packaged in AAV vectors to block harmful splice sites and restore healthy RNA and protein levels. In cell cultures and a humanized mouse model, this strategy improves axon growth and supports the idea that multiplexed RNA-targeted therapies could correct multiple disease pathways at once. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 41166]

RNA binding proteins help cells control how genetic information becomes working proteins, and Gene Yeo, Ph.D., M.B.A., at UC San Diego investigates how their disruption contributes to neurodegenerative disease. Yeo focuses on ALS, a severe motor neuron disease in which the RNA binding protein TDP-43 moves from the nucleus to the cytoplasm, loses normal RNA processing functions, and triggers cryptic exons that damage key neuronal genes, including one linked to motor neuropathy. His group maps these RNA changes and develops small nuclear RNA guides packaged in AAV vectors to block harmful splice sites and restore healthy RNA and protein levels. In cell cultures and a humanized mouse model, this strategy improves axon growth and supports the idea that multiplexed RNA-targeted therapies could correct multiple disease pathways at once. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 41166]

RNA binding proteins help cells control how genetic information becomes working proteins, and Gene Yeo, Ph.D., M.B.A., at UC San Diego investigates how their disruption contributes to neurodegenerative disease. Yeo focuses on ALS, a severe motor neuron disease in which the RNA binding protein TDP-43 moves from the nucleus to the cytoplasm, loses normal RNA processing functions, and triggers cryptic exons that damage key neuronal genes, including one linked to motor neuropathy. His group maps these RNA changes and develops small nuclear RNA guides packaged in AAV vectors to block harmful splice sites and restore healthy RNA and protein levels. In cell cultures and a humanized mouse model, this strategy improves axon growth and supports the idea that multiplexed RNA-targeted therapies could correct multiple disease pathways at once. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 41166]

RNA binding proteins help cells control how genetic information becomes working proteins, and Gene Yeo, Ph.D., M.B.A., at UC San Diego investigates how their disruption contributes to neurodegenerative disease. Yeo focuses on ALS, a severe motor neuron disease in which the RNA binding protein TDP-43 moves from the nucleus to the cytoplasm, loses normal RNA processing functions, and triggers cryptic exons that damage key neuronal genes, including one linked to motor neuropathy. His group maps these RNA changes and develops small nuclear RNA guides packaged in AAV vectors to block harmful splice sites and restore healthy RNA and protein levels. In cell cultures and a humanized mouse model, this strategy improves axon growth and supports the idea that multiplexed RNA-targeted therapies could correct multiple disease pathways at once. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 41166]

Ian Reid and Erik Kuhre discuss the Sharks signing forward Kiefer Sherwood to a 5 year, $5.75 million AAV deal from a quiet Stanley's Sports Bar at Sharks Ice. Teal Town USA - A San Jose Sharks' post-game podcast, for the fans, by the fans! Subscribe to catch us after every Sharks game and our weekly wrap-up show, The Pucknologists!
 Check us out on YouTube and remember to Like, Subscribe, and hit that Notification bell to be alerted every time we go live!


Are you holding yourself back from biotech roles because you don't check every box on the job description? You're not alone, and it's costing you opportunities.In this career chat, Carina sits down with Heer Shah, a Scientist in cell and gene therapy at Ensoma, a Boston-based biotech developing precision gene therapies using synthetic viral vectors and gene editing technologies. Heer has over seven years of biotech experience spanning vaccines, AAV, lentiviral vectors, VLPs, and LNPs, with roles at Merck, Intellia Therapeutics, Ring Therapeutics, and Sana Biotechnology. Heer holds a Master's in Biotechnology from Northeastern University, where the co-op program launched a career built on hands-on industry experience from day one. Today, Heer does vector engineering and gene editing optimization for programs targeting sickle cell disease and immuno-oncology.Heer shares how foundational lab skills and a big-picture mindset opened doors at every stage, and what it really takes to build a long-term biotech career across multiple modalities.Key takeaways from this episode:Why job descriptions are wish lists, not checklists, and why hiring managers value learning ability over a perfect resume matchHow to position diverse experience across biotech modalities as a competitive advantageThe difference between specialists and integrators, and why companies need bothWhat it's like surviving multiple rounds of biotech layoffs and how to build career resilienceHow the Northeastern co-op program helped Heer explore different company sizes and career paths before committingWhy behavioral interview questions often matter more than technical onesHow international scientists can navigate visa pathways, including the National Interest WaiverThe career advice Heer wishes someone gave earlier: tell your story soonerWhether you're early in your biotech journey or navigating a career transition, this conversation is packed with practical advice on building transferable skills, staying adaptable, and landing roles you're excited about.Want scripts, practice drills, and feedback from peers in biotech?Join our Biotech Career Coach Skool community: https://www.skool.com/biotech-career-coach/aboutConnect with Heer on LinkedInLearn more about the Collaboratory Career Hub community and access our free resources:Join our Skool CommunityTake the Free 7-day Interview Sprint ChallengeCheck out our sister podcast: Building BiotechsSend Carina a connection request on LinkedIn!Stay connected with us:

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.Today, we delve into the latest from an industry that continues to break new ground in both scientific innovation and regulatory landscapes. The pharmaceutical and biotech sectors are buzzing with activity as companies engage in bold strategies and face significant challenges in their quest for groundbreaking treatments.A recent event illustrating the high-stakes nature of this industry involves Novo Nordisk and its decision to conduct a head-to-head clinical trial for Cagrisema against Eli Lilly's Zepbound. This trial, which typically occurs post-approval, was conducted at the candidate stage. Novo Nordisk aimed to establish market dominance by proving superiority early on. However, the trial did not go as planned, with Cagrisema failing to outperform Zepbound. This outcome serves as a reminder of the competitive dynamics in early-stage testing and the strategic risks companies are willing to take in their bid for market leadership.Meanwhile, Gilead Sciences has made a bold move with a $7.8 billion investment in Arcellx, focusing on CAR T-cell therapy. This investment highlights Gilead's commitment to advanced cancer treatments, particularly Anito-cel for relapsed or refractory multiple myeloma. CAR T-cell therapies involve modifying a patient's T-cells to target cancer cells more effectively, representing a significant leap forward in oncological treatments. With an FDA decision anticipated by December 2026, Gilead's investment underscores its strategic focus on transformative therapies that could redefine cancer care.In legal news, Regenxbio has secured a notable victory against Sarepta Therapeutics regarding adeno-associated virus (AAV) technology patents. The appeals court ruling in favor of Regenxbio emphasizes the intricate nature of patent law in biotechnology, where innovations often intersect with naturally occurring biological processes. This decision not only solidifies Regenxbio's intellectual property but also sets a precedent for future patent disputes within the sector.On the regulatory front, Vanda Pharmaceuticals has rebounded from previous setbacks by securing FDA approval for drugs targeting bipolar disorder and schizophrenia. This achievement marks a promising shift for Vanda, demonstrating resilience and adaptability in redirecting focus towards neuropsychiatric conditions. The approval expands therapeutic options for these complex disorders, addressing long-standing unmet needs within mental health care.Despite these advancements, some areas continue to face hurdles. Gene therapies like Casgevy and Lyfgenia for sickle cell disease have struggled to gain traction two years post-launch. These therapies promise a one-time cure by correcting genetic defects but have encountered challenges in achieving widespread adoption. The difficulties reflect broader issues in transitioning from clinical success to market viability.Moreover, workforce reductions at major companies such as Bristol-Myers Squibb and Catalent signal structural changes within the industry. These layoffs may indicate shifts in strategic focus or responses to evolving market pressures as companies strive for efficiency and innovation.Regulatory practices are also undergoing scrutiny as the FDA considers defaulting to single clinical trial requirements for drug approvals. While this move could streamline development processes, it raises concerns about maintaining rigorous safety standards—a balance that remains crucial as companies push to bring innovative treatments to market swiftly yet safely.The dynamic nature of this industry is further highlighted by Candel Therapeutics' recent $100 million royalty deal aimed at launching its prostate cancer treatment. This strategic move underscores growing interest in innovative oncology solutions thaSupport the show

Detroit Tigers fans, the "rebuild" is officially a thing of the past. In one of the most explosive weeks in franchise history, the Tigers have solidified a rotation that isn't just the best in the AL Central—it might be the best in baseball.In this episode of Buffed Up Sports, I break down the two massive moves that have shifted the MLB landscape:⚾ Tarik Skubal's Historic PaydayTarik Skubal didn't just win his arbitration case; he broke the bank. By being awarded $32 million, Skubal has set the record for the highest arbitration salary in MLB history. I discuss the massive $13 million gap between the team and the player and what this means for a long-term extension in Detroit.⚾ The Framber Valdez BlockbusterThe Tigers landed their second ace by signing Framber Valdez to a 3-year, $115 million deal. At a staggering $38.33 million AAV, Valdez is now the highest-paid left-handed pitcher per year in the history of the game.⚾  Is it World Series or bust for Detroit in 2026Don't forget to LIKE, SUBSCRIBE, and hit the BELL to stay Buffed Up on all things Detroit sports!Comment Below: Does this rotation make the Tigers the favorites to win the World Series this year?

Ben Verlander previews the World Baseball Classic now that the rosters have been set. He also talks about the best lineup, rotation & team in the WBC. The Detroit Tigers surprised the baseball world by giving Framber Valdez the highest AAV for the left-handed pitcher & Tarik Skubal also won his record arbitration deal. That and so much more on Flippin' Bats. CHAPTERS:00:00 INTRO01:30 TIGERS SIGN FRAMBER VALDEZ07:00 TARIK SKUBAL'S RECORD DEAL18:00 WORLD BASEBALL CLASSIC PREVIEW19:30 POOL A23:10 POOL B29:00 POOL C31:50 POOL D35:50 BEST LINEUP38:30 BEST ROTATION39:50 BEST TEAM42:50 TOP 10 TEAMS46:30 OUTRO Learn more about your ad choices. Visit megaphone.fm/adchoices

Benny & the Wings! This Detroit Red Wings podcast breaks down Ben Chiarot's new three-year, $3.85 million AAV extension & whether it was a good signing by Yzerman. Our Detroit Red Wings news and analysis covers the contract details, Simon Edvinsson's injury update, and the playoff race heating up in the Atlantic Division. (00:00) - Intro & Red Wings Gift Surprise Special delivery from the Detroit Red Wings organization sets up an exciting episode finale. (04:15) - Ben Chiarot Extension Breakdown We debate the merits & drawbacks of the new contract as Chiarot takes a pay cut to stay in Hockeytown for 3 more years, avoiding 35-plus contract complications with straight salary structure. We discuss how Chiarot provides veteran leadership & snarl as Detroit builds depth behind Moritz Seider and Simon Edvinsson on the blue line. (23:30) - Simon Edvinsson Injury Update Latest news on Edvinsson's status and what it means for Todd McLellan's defensive pairings. (27:50) - Kings Game Recap & Analysis Red Wings' anemic performance against Los Angeles, including DeBrincat's sole Detroit goal, Patrick Kane tying Mike Modano's record, and key takeaways from the matchup. (36:50) - Atlantic Division Playoff Race Standings update as Detroit battles for positioning in the competitive Atlantic Division landscape, as the Buffalo Sabres are still surging. (44:40) - NHL Trade News & Market Analysis League-wide moves and how they impact Steve Yzerman's approach to the trade deadline, and whether players like Schneider or Panarin are worth it from the Rangers. Also, more not-so-joking jokes about acquiring Robert Thomas and Justin Faulk. (54:50) - Overtime Q&A Listener questions on the Chiarot deal, defensive depth, and Red Wings roster construction moving forward. (1:06:15) - Red Wings Surprise Gift Reveal --- WWP Night at the LCA Night (March 21st) tickets at wingedwheelpodcast.com/redwings This episode is brought to you by Hims. Visit hims.com/wingedwheel for your personalized hair loss treatment options. Support the show: Patreon.com/WingedWheelPodcast Head over to wingedwheelpodcast.com to find all the ways to listen, how to support the show, and so much more!

Kyle Sucker—heh!—and Blow Bichette—get it?—are significantly wealthier today than they were a week ago, having freshly signed incredibly lucrative high-AAV, opt-out-laden free agent contracts with the Los Angeles Dodgers and New York Mets respectively. But are Blue Jays fans the suckers here for expecting more from their front office? Did Ross Atkins and company blow their opportunity to truly become one of the game's elite franchises?DISCUSS!** FOR AN AD-FREE VERSION OF THIS—AND EVERY—EPISODE, PLUS WEEKLY BONUS SHOWS, FIND US AT patreon.com/BJHH ** Hosted on Acast. See acast.com/privacy for more information.

Welcome to Daily Faceoff Live with Tyler Yaremchuk and Carter Hutton!We start the show with an Atlantic overtime battle in Toronto. Moritz Seider bullied Easton Cowan off the puck in the extra frame before feeding it to Red Wings captain Dylan Larkin for the OT winner.We stick in the Atlantic as the Buffalo Sabres locked up Josh Doan on a 7-year contract extension at $6.95 AAV. Can we say the JJ Peterka trade was a win-win for Utah and Buffalo? With one player locked up all eyes remain on Alex Tuch and his potential future in Buffalo, what does David Pagnotta have to say about a possible Tuch deal?Summer brings back great memories, but are all teams happy with their summer moves? We'll look at some summer wins and losses from this past off-season.Jonny Lazarus from Morning Cuppa Hockey and Tri-State Hockey joins the show to discuss the disaster of a season for the New York Rangers. We'll talk Shesterkin/Fox injuries, Jonathan Quick, Artemi Panarin, and look ahead to what could be a very active off-season for the blue shirts.SHOUTOUT TO OUR SPONSORS!!

We're speculating about whether short-term, high AAV contracts are becoming the new norm in MLB. -Elly Turns Down Record Contract -Mookie Will Retire After 2032 -Verlander's Next Team -HOF Reveal Tuesday -Jayhay's Bichette Takes -Sal Frelick Tomorrow! Use promo code “Jared” to get up to $1000 in bonus credits AND a special pick on Underdog! PLAY HERE: https://play.underdogfantasy.com/pc-d2PyPbHAPu 0:00 - Trying New Food 10:10 - NFL Playoffs 14:35 - Reds / Elly Offer 22:00 - New CBA 25:15 - Guess That Player 37:02 - Betts Retirement 40:00 - Tide Shift 47:00 - Verlander Interest 1:00:35 - HOF Reveal 1:12:37 - Jayhay Nuggs 1:13:30 - Final Thoughts Learn more about your ad choices. Visit megaphone.fm/adchoices

The Red Sox are connected to a plethora of potential trade candidates - some we like (Nico Hoerner) more than others (Brendan Donovan). Like, significantly more. There was also plenty of record setting and record cucking news in baseball this week - including Kyle Tucker to the Dodgers on the largest AAV contract ever given out, and Bo Bichette to the Mets on the Bregman sweetheart deal. The Mets are the weirdest group of infielders I think I've seen, maybe ever. Paredes is the most likely option to end up in Boston, but he is just not worth a singular Brayan Bello or Jarren Duran. We think by next week, SOMETHING falls into place (like the long Tetris piece). Linktree NASP Instagram NASP Twitter Ian's Twitter Jack's Twitter Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The Los Angeles Dodgers signed Kyle Tucker to the highest-AAV deal in MLB history just days ago — in fact, it's not even official yet — but to hear the rumors, the might not be done yet. Are they really in on Brewers pitcher Freddy Peralta as multiple reports suggest? Other reports say the Red Sox are interested in LA's backup catcher, Dalton Rushing — what could the return be for a package headlined by such a top prospect? Jeff Snider is here to talk about all of this, plus some of the social media crying about the "unfair advantages" the Dodgers have. Will it be unbiased? No, but as always, Jeff will bring the facts. Oh, and then we hung around and talked with the live chat for a couple more hours. Country music, cheese, bobbleheads. You name it, we probably talked about it. Tube in all offseason long! Leave a voicemail or text the Friend of the Show hotline! = (562)373-4095 #Dodgers Join our Discord by supporting the show on Patreon! ️ https://patreon.com/realFRG Or on YouTube Members! ️ https://youtube.com/@alldodgers/join All Dodgers is presented by FanDuel, part of the Bleav Network of podcasts. Please like and subscribe on YouTube! Hit that notification bell to get alerts on new content! PODCAST: Listen on BLEAV! ️ https://bit.ly/adbleav Listen on iTunes! ️ https://apple.co/3TXL8Vv Listen on Spotify! ️ http://bit.ly/3I9nW2S Listen on iHeart! ️ https://ihr.fm/3TXV5Cy SOCIAL: Follow Clint on Twitter/X ️ twitter.com/realFRG Follow Clint on Instagram ️instagram.com/realfrg Follow Jeff on Twitter/X ️ twitter.com/snidog Follow Kevin on Twitter/X ️twitter.com/skinner7kevin Follow the show on Twitter/X ️ twitter.com/alldodgersla Follow the show on Instagram ️ instagram.com/alldodgerspod Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Segment 1 – News and Notes1.    The Dodgers made a splash by signing Kyle Tucker to the largest AAV in history – 4 years and $240 million with opt-outs after 2027 and 2028.8.a.    A lot of people are upset about the dominance of the Dodgers.  “They are ruining baseball!”  What say you?b.    Were you surprised that Tucker signed a shorter deal but for more money?c.    The odd thing is that he's not even the best player on the team, maybe not even the top 3 players on the team.d.    I don't see any playing time loss for anyone with the exception of a potential delay in the arrival of Josue DePaula or Zyhir Hope.  Do you see anything?2.    The Mets were spurned by Tucker and pivoted to Bo Bichette, signing him to a massive three-year, $126 million deal with a unique opt-out clause.  He can opt out after each year, and if he does, the Mets have to pay him a $5 million bonus. a.    $42 million a year for Bichette?  Thoughts on the signing?b.    He'll likely play third base.  Who sits out of Baty or Vientos?c.    Also, I think Jett Williams needs to learn the outfield, plus, with the Mets not getting Tucker, Benge is still safe – for now.  Thoughts?3.    A small but interesting, three-way trade was pulled off by the Angles, Rays and Reds.  The Rays sent Josh Lowe to the Angels and Gavin Lux to the Rays, with the Reds acting as the intermediary. The Angels shipped RHP Chris Clark to Tampa Bay and LHP Brock Burke to Cincinnati.a.    Who's value goes up more?  Lowe, Lux, or neither?b.    Does this open a chance for Jacob Melton in Tampa?c.    Will Lux ever be more than an afterthought?Segment 2 – Third Base Rankings for the 2026 Season1.    How are you approaching this position for your upcoming drafts?2.    We will break down the top 15 to 20 in detail.  Then, go through 20 to 30 in less detail.  We will end by jumping around the remaining ranked players.3.    Which player not in the Top 10 has a chance to emerge there next season?4.    Which Top 10 player will not be there next season?5.    Give me a couple of sleepers6.    Give me one, maybe two guys you are just going to avoid drafting?

The show comes to a screeching halt with legitimate breaking news as the Mets land Bo Bichette on a three-year, $126 million deal, and Evan immediately reminds everyone he called the pivot before it happened. Evan and Tiki react in real time to the signing, the massive AAV, the opt-out structure, and what this move says about how David Stearns is operating in the market. They break down where Bichette fits defensively, why third base appears to be the early plan, and how much offensive ground this actually recovers after losing Pete Alonso and Kyle Tucker. The guys debate the risk of one-year and two-year opt outs, the surprising draft pick cost, and whether this is a necessary concession in today's marketplace. Plus, what this move means for Philadelphia after reportedly agreeing to a long-term deal, how Toronto now pivots, why Cody Bellinger still does not make sense for the Mets, and whether this finally changes the tone of a chaotic Mets offseason. Live calls, instant reactions, and a full breakdown of how the roster and expectations shift after the biggest move yet.

Evan unloads a full conspiracy theory: Rob Manfred is not mad about the Dodgers dominating baseball, he's thrilled. The idea is simple and terrifying. Let the Dodgers keep stacking stars, let fans scream “baseball is broken,” and then use that outrage to win the PR war for a salary cap the players will hate. Tiki buys it immediately, even as they admit it still might never work. From there, the focus snaps back to the Mets problem that keeps getting louder: they can “try” for Tucker, but where's the backup plan? A caller compares Cashman's quick Soto pivot to the Mets dragging their feet, and the guys dig into the bigger issue: Stearns will spend huge AAV, but refuses to go long term, which kills half the market. Then it turns into pure show chaos: Free Agent Bingo standings, Knicks misery, and Mets fans roasting the offseason, including a fake “Mets fan” troll call and the return of the “chomping at the bit” debate right before Evan teases a pivot plan that does not include Cody Bellinger.

With Kyle Tucker off the board, the Mets are staring into the void and Evan lays out why Cody Bellinger is not a realistic “panic buy,” even with rumors of the Yankees sitting around five years and $160M. If the Mets wouldn't go long for Tucker or Alonso, why would they suddenly cave to Scott Boras? Then the debate turns into the uncomfortable part: what's the actual pivot? Evan pitches a wild, short-term, mega-AAV idea for Bo Bichette that's basically a Tucker-style offer to blow him away, get an opt-out, and take another swing at free agency before 30. The problem: where does he play, and how much run prevention are you willing to sacrifice to get a real bat? Tiki pushes back on the defensive domino effect, the “versatility” trap, and the weekly second-guessing Mets fans would live through. The guys kick around the alternatives (including a one-year Eugenio Suárez power play), plus why pitching still has to be the priority no matter what. And of course, the segment ends with the same challenge: if you hate the plan, tell us a better one.

Episode 132 of Tablesetters is an emergency reaction pod centered on a market-shifting decision, as Kyle Tucker agrees to a four-year, $240 million deal with the Los Angeles Dodgers, immediately resetting both the top of the free-agent market and the competitive landscape heading into 2026. We open with the deal itself, breaking down how a $60 million AAV contract represents a decisive pivot away from traditional long-term free-agent structures and toward compressed risk at the very top of the market. We discuss why Tucker and the Dodgers were uniquely aligned on this structure, how Los Angeles leveraged competitive certainty and roster context over sheer length, and what this agreement signals about where elite player negotiations may be heading. From there, we examine the broader market fallout. Tucker's decision effectively closes the door on the Mets' reported $50 million-per-year short-term push and the Blue Jays' long-term pursuit, while clarifying how teams are increasingly being forced to choose between flexibility and security. We explore how this signing reshapes leverage for remaining free agents and how quickly the rest of the offseason could now accelerate. We then turn to the on-field implications in Los Angeles. Tucker's arrival addresses a clear offensive inefficiency in the Dodgers' outfield, particularly in on-base ability, while raising both the floor and ceiling of a lineup already built to contend. We break down the inevitable roster ripple effects, including the pressure this puts on depth pieces and the difficult decisions that follow when a true superstar enters the mix. Finally, we zoom out to the long view. We discuss the draft and development costs attached to signing another qualifying-offer free agent, why the Dodgers were willing to absorb them, and how this move fits within an organization balancing immediate championship windows with a steady pipeline of young talent nearing the majors. Steve and Devin connect the dots between financial creativity, competitive leverage, and roster timing, framing the Tucker signing as more than a splash — it is a signal about how the next phase of team building at the top of the sport may look. ⚾️ An emergency decision, a market reset, and a defining move of the offseason.

Episode 133 of Tablesetters is a live, solo emergency reaction to the New York Mets signing Bo Bichette to a three-year, $126 million contract, a deal that immediately reframes the Mets' offseason after missing on Kyle Tucker. This episode focuses on why this was not a fallback move. We break down the structure of the contract, the $42 million AAV, the opt-outs, and the absence of deferrals, and explain how it mirrors the same short-term, high-value philosophy the Mets pursued with Tucker. The player changed. The strategy did not. We also examine the market context that sharpened the decision. According to Bob Nightengale, the Philadelphia Phillies believed they had Bichette locked up on a seven-year, $200 million deal before the Mets stepped in. Rather than matching length and risk, New York leveraged annual value and optionality, reshaping both the division and the market in the process. From there, we dig into what the Mets are actually buying on the field, how Bichette's 2025 season reestablished his offensive ceiling, and why the club appears comfortable with the defensive trade-offs at third base given their infield alignment and roster depth. This is not a full teardown. It's a focused reaction on leverage, roster timing, and what this move says about how the Mets are choosing to compete right now. ⚾️ A fast pivot, a clear philosophy, and another defining contract in a rapidly evolving offseason.

Episode 131 of Tablesetters is a reaction pod focused on a pivotal stretch of the offseason, as a major pitching commitment in Boston, a franchise-defining signing in Chicago, a stalled superstar market, and a rare ballpark adjustment collectively show how teams are adapting to risk, scarcity, and roster timing heading into 2026. We open in Boston, where the Red Sox are set to sign left-handed pitcher Ranger Suárez to a five-year, $130 million contract with no deferrals, no opt-outs, and no no-trade protection. The deal represents the largest free-agent commitment of Craig Breslow's tenure and a clear pivot back toward rotation strength after Boston stalled in its pursuit of an infield upgrade. Suárez joins a rotation led by Garrett Crochet and recently bolstered by Sonny Gray and Johan Oviedo, signaling a belief in run prevention, depth, and managed workloads over chasing innings volume. From there, we shift to Chicago, where the Cubs make the biggest offensive splash of their offseason by signing Alex Bregman to a five-year, $175 million deal with significant deferrals. We break down why this move reshapes the Cubs' lineup, how it reflects a philosophical shift from the Ricketts family, and what Bregman's arrival means for the infield picture alongside Dansby Swanson, Nico Hoerner, and Matt Shaw as Chicago pushes firmly into a win-now posture. Next, we zoom out to the top of the free-agent market, where Kyle Tucker remains unsigned. We discuss reports that the Mets have offered a short-term deal with a $50 million average annual value, while the Blue Jays have made a long-term offer, highlighting the growing divide between extreme AAV flexibility and traditional long-term guarantees — and why Tucker's decision could reshape the rest of the offseason. We close in Kansas City, where the Royals announce changes to the outfield dimensions at Kauffman Stadium, moving in the fences in both corners and the alleys while lowering wall height. We explore why this calculated adjustment is aimed at boosting offense without compromising pitching, how it aligns with the Royals' left-handed core, and what it says about teams looking for marginal gains beyond the roster itself. Steve and Devin connect the dots between market behavior, roster construction, financial flexibility, and environment, focusing on how these moves reflect a league increasingly split between certainty, creativity, and controlled risk. ⚾️ One week, four signals, and a clearer picture of how contenders are being built.

The Mets offseason is at a tipping point, and Kyle Tucker is the one move that could change the entire mood. Evan and Tiki debate why Tucker would “save” the winter, why the Mets' only real edge is money, and how David Stearns' short-term, high-AAV philosophy is shaping everything after losing Pete Alonso. Then it turns into a wild New York sports morning: John Harbaugh meets with the Giants, fans call in on Tucker vs pitching help (Suarez, Valdez, Giolito), and the guys hit the Yankees' under-the-radar Ryan Weathers trade before circling back to the big question: who's the Mets ace right now? Chapters 00:00 Kyle Tucker “saves” the Mets offseason 03:20 Mets vs Dodgers vs Blue Jays and what actually matters 06:25 Trusting Stearns, roster “maybes,” and the first base frustration 14:00 Giants news: John Harbaugh meeting and the Tisch plane buzz 18:30 Calls: Tucker vs Suarez/Valdez, plus the rotation anxiety 35:15 Yankees add Ryan Weathers, then Giolito and the Mets “ace” debate

Evan and Tiki open the phones and Mets fans go straight to the big question: if you can only make one marquee move, is it Kyle Tucker or a top arm like Ranger Suárez or Framber Valdez? Evan argues Tucker's 162-game impact is bigger than any starter's, even while admitting the rotation still screams for certainty. The conversation rolls into David Stearns' short term, high AAV strategy, whether “connections” matter at all in free agency, and why the Dodgers are always lurking if money is close. Plus: the Pete Alonso fallout won't go away, the “is $50M worth it?” camps battle, the Yankees finally make an under the radar move with Ryan Weathers, and a caller throws Lucas Giolito into the mix as the show debates what actually qualifies as a Mets ace right now.

Rumors broke that the Mets have offered free agent OF Kyle Tucker a short-term, high-AAV deal. Chris and Jack break down what it could mean for their offseason outlook and 2026 lineup. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The Mets are making a real push for Kyle Tucker, with reports of a massive short term, high AAV offer that fits David Stearns and Steve Cohen's recent roster philosophy. The crew debates whether the Mets can actually beat out the Dodgers or Blue Jays, and why Tucker might prefer a short deal to reenter a thin future free agent market.

While Wild Card Weekend dominated the headlines, a major MLB bomb dropped in the background. The New York Yankees are now operating under the assumption that Cody Bellinger could sign elsewhere as contract talks stall over years, not dollars. Evan, Tiki, and Shaun break down the reported standoff with Scott Boras, why the Yankees are refusing to negotiate against themselves, and why this situation feels eerily similar to what the New York Mets dealt with last year. The conversation pivots to potential fallback options, including interest around Kyle Tucker, the realities of short term high AAV deals, and why teams like the Los Angeles Dodgers and Toronto Blue Jays loom large in the background. Plus, a deeper debate on free agency leverage, market reality, and why Yankee fans may want to stay calm as this staring contest plays out.

Welcome to the DFO Rundown with Jason Gregor and Jeff Marek! We start the show with an update from Gregor on the double Gordie and if it has been done before.New Jersey is having a very dysfunctional season, and the Dougie Hamilton saga could drag on with him having 2 years left at $9m AAV and a modified no-trade list. The Rangers got a ten-spot from the Boston Bruins over the weekend in an embarrassing 10-2 loss. Will Artemi Panarin be moved out of the Big Apple?The Buffalo Sabres are back to winning ways after their ten-game streak was snapped as they're on a three-game heater now. The Ottawa Senators have had some off-ice issues recently, but the on-ice issues might be of greater concern, as they search for answers. Can James Reimer help the goaltending in Ottawa?Vancouver has Thatcher Demko back on IR, but is this good for the Canucks in their hunt for a top draft pick? Is the hate around Gavin McKenna valid or is he still worthy of being number one overall?The Anaheim Ducks had a great start, but the young defensive core has burst at the seams. Lukas Dostal has struggled since returning from injury and the pucks are filling the Ducks' net.Zack joins the show for an edition of Buy or Sell:- The Leafs will be in a playoff spot come the Olympic break- The current Hart Trophy winner is Macklin Celebrini- The Sabres will be playoff contenders and a buyer at the deadlineA star-studded list of NHL players have had 28-plus-game point streaks, can Connor McDavid become just the fourth active player to get a 20+ game point streak?Connor McDavid is shooting a lot more and the points are piling up. Can Connor McDavid be any style of player? The superstars in the NHL don't get talked about enough, there's a lot of “and buts” around the NHL with Nathan MacKinnon is great this year but he hasn't won a Hart, Connor McDavid is great, but he's never won the Cup. The NBA doesn't have the same issue; how can the NHL change this?Marek got to meet Red Berenson and talk about Glenn Hall, Michael Hage, TJ Hughes, and Brandon Naurato. Quinn Hutson leads the AHL in goals as a rookie.The Nashville Predators are bucking some trends as they've moved up the standings to just trail the second wildcard spot. Winning while conceding the first goal, can the Preds make the playoffs? Alexander Ovechkin got goal number 20 on the season. He's second behind Gordie Howe for most 20-goal seasons trailing the legend by one season. Can Ovi chase 1000 goals? Hosted on Acast. See acast.com/privacy for more information.

Bo Bichette is reportedly unlikely to re-sign with the Toronto Blue Jays, and Kyle Tucker might have to take a short-term, high-AAV (average annual value) deal. Both of those developments could favor the Los Angeles Dodgers in their potential pursuit of one or both of the top two offensive free agents. Could this be real? Clint Pasillas and Jeff Snider are here to talk about it! Tube in all offseason long! Leave a voicemail or text the Friend of the Show hotline! (562)373-4095 Join our Discord by supporting the show on Patreon! patreon.com/realFRG Or on YouTube Members! youtube.com/@alldodgers/join All Dodgers is presented by FanDuel, part of the Bleav Network of podcasts. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Welcome to Daily Faceoff Live with Tyler Yaremchuk, David Pagnotta and Steven Ellis!We start the show with an injury update in Toronto. Defensive stalwart Chris Tanev will likely miss the remainder of the regular season after considering surgery for a groin injury. How can the Leafs replace the veteran shutdown defender?The San Jose Sharks have signed center Alex Wennberg to a three-year contract extension with a $6 million AAV. The Sharks still have eight pending UFAs on their roster and are projected to have just under $50 million in cap space for next season. Will San Jose make any big splashes at the trade deadline or over the summer to bolster their young, talented core?The Vancouver Canucks continue to sit at the bottom of the Pacific Division, and trade talk is heating up around power forward Kiefer Sherwood. Meanwhile, the Nashville Predators are climbing the standings, but could veteran forward Steven Stamkos still be on the move as contending teams look to add a proven winner ahead of a potential Stanley Cup run?Steven Ellis joins the show for a World Juniors Gold Medal Preview. We'll talk about Canada's loss to Czechia, how this year compares to recent tournaments, the Czechia–Sweden matchup, how top draft-eligible players have performed, and his medal predictions for tonight.SHOUTOUT TO OUR SPONSORS!!

We love to hear from our listeners. Send us a message.In episode 119 of Cell & Gene The Podcast, Host Erin Harris talks to Dr. Norman Putzki, Global Head Clinical Development, Novartis, about the FDA approval of Itvisma, now the only gene replacement therapy approved for children, adolescents, and adults with spinal muscular atrophy (SMA). Dr. Putzki walks us through the six-year development journey behind the STEER and STRENGTH Phase 3 programs. And we explore what the expanded age-range label means for patients who were previously left behind, why intrathecal, fixed-dose AAV delivery represents a pivotal advance for safety, efficacy, and scalability. He details how the Itvisma program is informing Novartis' broader gene therapy strategy across neuromuscular and CNS diseases, and more.Subscribe to the podcast!Apple | Spotify | YouTube Visit my website: Cell & Gene Connect with me on LinkedIn

The Tampa Bay Lightning beat the Florida Panthers 4-2 in a game that saw them take 26 penalties and go on the penalty kill 10 times. Jake Guentzel tied Brandon Hagel for the team lead with 18 goals, Pontus Holmberg scored his 5th goal and Nikita Kucherov got his 61st career game-winning goal. The Lightning's penalty kill went 9-for-10 on the night. Before the game JJ Moser signed an 8-year extension worth $6.75 million AAV. The Lightning host the Montreal Canadiens this afternoon at Benchmark International Arena.See omnystudio.com/listener for privacy information.

Julie A. Parsons, MD Haberfield Endowed Chair in Pediatric Neuromuscular DisordersProfessor of Clinical Pediatrics and NeurologyUniversity of Colorado School of Medicine, Children's Hospital ColoradoAurora, CO, USAAs we talk about the gene transfer therapies and the modalities that we have to use, it's really interesting. Yesterday, with our keynote speaker, you could see this logarithmic growth of the use of gene transfer therapies for these disorders. If you look at the Venn diagram, you can see that really 27% almost of gene transfer therapies that are used are in musculoskeletal and neurology. For many of us as neurologists, we also take care of metabolic disorders.We really own right now this landscape, and of course, our two approved modalities are Onasemnogene and Delandistrogene. We're going to look at three different disorders, monogenic disorders, monogenic diseases, to typify what we look at in terms of some of the risks and benefits of these treatments. SMA, Duchenne, and X-linked myotubular myopathy are all rare disorders. They're all diseases that have a high unmet medical need and a significant disease burden.I think they're all good in terms of typifying where we are clinically with these disorders. The first question is, is it worth it? Are these effective treatments? We know from looking at the information about SMA that just looking early on, we know that if we treat kids early, that we do see a marked improvement in motor scores for kids that are treated early with Onasemnogene.In Duchenne, we have information that there is at least some improvement in the 4-5-year-olds in terms of motor skills treated with Delandistrogene. In terms of X-linked MTM, which was a very dramatic improvement, you could see that for boys who were basically traked, vented, and had no mobility, the bottom line, the blue line, is actually looking at ventilator dependence. Are they effective? Yeah, they're effective, but then we have to say, okay, what's the downside?The downside is that there's tremendous risk associated with treatment with these agents. If we really look at the sobering facts, we know that with SMA, there have been deaths, there have been fatalities related to thrombotic microangiopathy to patients who have liver failure, a couple of patients have died. With Onasemnogene, this is 4,000 plus doses that have so far been given. With Duchenne, unfortunately, many of us got the letter yesterday talking about an additional death in a patient treated with commercial Delandistrogene.We also know with some of the other agents, like fordadistrogene, patient died of heart failure, cardiac arrest, another patient who had acute respiratory syndrome with pulmonary edema. Again, we look at this and say this is significant. With X-linked MTM, as Alan said, there were some unanticipated deaths, four deaths from patients who ended up having cholestatic liver diseases that really wasn't anticipated prior to the patients being treated with the animal models and all that we had. Then many of you have heard about the patient with Rett syndrome who had a systemic hyperinflammatory syndrome. Again, these are rare disorders. They have a high disease burden, but the risk of treatment is significant.In the next part, Dr. Parsons discuss factors impacting safety and efficacy of AAV-mediated gene therapies.

Julie A. Parsons, MD Haberfield Endowed Chair in Pediatric Neuromuscular DisordersProfessor of Clinical Pediatrics and NeurologyUniversity of Colorado School of Medicine, Children's Hospital ColoradoAurora, CO, USAHow have programs adapted to the experiences from clinical trials? I'm just looking at SMA because we've had SMA. We've had onasemnogene around for the longest period of time. We want to always confirm a diagnosis and know that the patient is right. We do antibody testing for these disorders prior to delivering the AAV therapies. We have to know that the product that is incredibly expensive is handled appropriately by the institution. Dealing with the pharmacy, making certain that you handle the agent properly, patients need to be pretreated at this point with prednisone, and that really has to happen so that you know that they're ready for treatment, that they don't have any infections prior to treatment.Then we need to monitor and provide medication and follow-up afterwards. As I said, I think this is really, really important to make sure that you're connected well with the patient. If you live in an area as we do, that has a huge catchment area with patients that come from hundreds of miles away, sometimes they need to stay with us for a period of time, so that we can ensure the safety and follow-up of these patients after we deliver gene therapies.Again, a recurring theme is the patients that you're treating who are not in a clinical trial are not the homogeneous, well-selected patients. It's really all actors. The population that you're treating commercially is very different. We're now moving into treating patients with larger body masses and older ages. We don't always know, because those patients haven't really been included in the clinical trials. We don't really know what some of the effects are going to be with that group of patients as well.I am a neurologist. I am not an immunologist. I have had to learn a lot of immunology at this point, but it's still not sufficient. I think that we also need to reach out to our subspecialist colleagues who really do have more experience than we do to try to help us with some of these issues, because as we look at these viral vector capsids and the transgenes, we have to say, is there something that we can do to mitigate the immune response that we're seeing when we're giving massive doses of these agents and really taxing the immune system in our patients?Looking at possibilities, we give steroids, and that's really what we've done. That was what was done in the early clinical trials with MENDEL. It's like, okay, prednisone, that's all we have to do is we give steroids and everybody will be fine. That really isn't maybe the answer. As we have more information, we know that we're going to start with steroids, but we're really going to look at, is there a way to block both the B-cell response, the T-cell response? Is there something that we can do so that we don't have to sit on the edge of our seats and not sleep for months after we treat these patients?At least in a trial, was done looking at patients who were treated just with corticosteroids. Those patients had rapid increases in IgM and IgG. There's complement activation. Both the adaptive and the acute immune responses are triggered. That's really what we're doing as standard practice right now, but in the trial looking at treating patients and pretreating patients with rituximab blocking B cells and sirolimus and corticosteroids, then no significant change in IgM, IgG.Is that something that we should be doing? I think that some of the clinical trials that are being set up are looking at instituting some of these immune-modulating features to see whether or not their outcomes are improved. Can we do anything proactively to prevent our patients from having some of these very severe events or fatalities? I think that's really what we need to be looking at now. I think we are looking at that as a community, and to me, is a story that is still unfolding in terms of how we keep our patients safe.In the next part, Doctors Beggs and Parsons will discuss key issues on gene therapy development.

Cody and Vince are live with a brand new episode of Talkin' Blue, breaking down the latest Dodgers and MLB news. Mookie Betts has officially decided not to participate in the upcoming World Baseball Classic, with his wife expecting their third child around that time. We discuss Mookie's decision, what it means for Team USA, and why family always comes first. The Kyle Tucker market remains open, and we explore whether a short-term deal with a higher AAV could make sense. Is Tucker waiting things out, and could the Dodgers still be lurking? Tyler Glasnow also addressed recent trade rumors and shared his excitement about the idea of playing alongside Tarik Skubal if the Dodgers were to land him. We break down what that would mean for the rotation and whether the buzz has real legs. Plus, more WBC news, roster chatter, and live fan reactions throughout the show. Tap in, join the conversation, and Talk Blue with us. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dodgers sign Edwin Diaz for 3 years! setting a AAV record for relievers. Giants get off their ass, kinda. They sign Jason Foley who wont be back til mid season and Adrian Houser to a 2 year deal with a 3rd year club option

2025 MLB Winter Meetings Recap: Schwarber Re-Signs with Phillies, Díaz to Dodgers, Alonso Joins Orioles & Post-Meetings Moves! Join us as we break down the action-packed 2025 MLB Winter Meetings in Orlando (Dec 8-11), featuring blockbuster free agent signings like Kyle Schwarber's 5-year, $150M return to the Philadelphia Phillies, Edwin Díaz's record AAV deal with the Los Angeles Dodgers, and Pete Alonso's 5-year, $155M pact with the Baltimore Orioles! We also cover post-meetings developments, including Kenley Jansen to the Tigers, Merrill Kelly back to the Diamondbacks, and ongoing rumors around Kyle Tucker, Tarik Skubal trades, and more offseason buzz as of December 15, 2025. From reliever reinforcements to slugger splashes, analyze how these moves reshape 2026 contenders! Perfect for MLB fans, fantasy baseball players, and hot stove enthusiasts. #MLBWinterMeetings2025 #MLBOffseason #KyleSchwarber #EdwinDiaz #PeteAlonso #MLBFreeAgency Subscribe for daily MLB hot stove updates, hit the bell , and share your thoughts in the comments! Who's the biggest winner of the offseason so far?

BT & Sal kick off the show with WWE Executive Director Bruce Prichard (aka Brother Love) to discuss John Cena's final match, the evolution of wrestling, and who is the "toughest legitimate alpha" in the locker room today. Then, the focus turns to the New York Mets after Edwin Diaz signed with the Dodgers. Sal explodes after learning the Mets offered three years, $66 million and the deal-breaker was Diaz's desire to be the highest AAV closer—revealing Diaz chose the Dodgers, not the money, but for the status. Sal's fiery retort labels Diaz a "traitor," slamming the trumpets, his 2019 disaster, and his 2024 sticky stuff suspension. The guys ultimately side with the "unkillable" duo of Steve Cohen & David Stearns, believing the organization will bounce back and address the team's many holes.

BT & Sal explode over Edwin Diaz's shocking defection to the Dodgers for a record AAV, concluding that the closer "didn't want to be a Met" and chose status over the Mets' near-matching $66M offer. Sal rips Diaz as a "traitor" while the hosts ultimately side with the "unkillable" duo of Steve Cohen & David Stearns as they brace for a rebuild. The chaos fuels a fierce debate over Pete Alonso's future, with Sal criticizing Pete for "shopping himself" at the Winter Meetings while his potential Hall of Fame pace is fiercely debated. They dissect Kyle Schwarber's new contract and its massive implications for Alonso's market price. The show is rounded out by a hilarious dive into obscure baseball slang and a serious sit-down with WWE Executive Bruce Prichard (Brother Love) about John Cena's final match and wrestling's toughest "alpha."

PG writer Noah Hiles joined the show. Noah said the offer to Kyle Schwarber from the Pirates was legitimate and actually higher than what he signed for, in AAV, with the Phillies. Noah said it's not worth celebrating because they didn't land the player, but this should mean the Pirates are willing to spend that money elsewhere. Noah didn't think it was a coincidence that the Pirates' offers were the ones that were openly put out there. Noah thinks it could tell other players that the Pirates are willing to spend, but it was probably leverage being played on both sides. How will the Pirates handle some of the other notable names on the market? Noah said Jorge Polanco is the top, realistic player on his list, but that shouldn't stop the Buccos from going after Ketel Marte. He said there are ways to get around a player's no-trade clause list, but it means they have to sweeten the deal. Noah believes the Pirates cannot show up ‘empty-handed' to Pirate Fest this year after the words that have been thrown around this off-season. Noah pointed to a particular agency that could be a way for us to follow the tea leaves.

Tomlin Takes – What else did Mike Tomlin say to the media today? PG writer Noah Hiles joined the show. Noah said the offer to Kyle Schwarber from the Pirates was legitimate and actually higher than what he signed for, in AAV, with the Phillies. Noah said it's not worth celebrating because they didn't land the player, but this should mean the Pirates are willing to spend that money elsewhere. Noah didn't think it was a coincidence that the Pirates' offers were the ones that were openly put out there. Noah thinks it could tell other players that the Pirates are willing to spend, but it was probably leverage being played on both sides. How will the Pirates handle some of the other notable names on the market? Noah said Jorge Polanco is the top, realistic player on his list, but that shouldn't stop the Buccos from going after Ketel Marte. He said there are ways to get around a player's no-trade clause list, but it means they have to sweeten the deal. Noah believes the Pirates cannot show up ‘empty-handed' to Pirate Fest this year after the words that have been thrown around this off-season. Noah pointed to a particular agency that could be a way for us to follow the tea leaves. Name Game.

Happy Thanksgiving… Thursday, November 27, 2025. Week 48.   Continued from #S10e189…   And the AAV Paper (https://pubmed.ncbi.nlm.nih.gov/40988338/) from #S10e187… https://curesyngap1.org/podcasts/syngap10/clinical-research-ai-dx-nl47-survey-autism-press-6-days-to-register-for-syngap1conf-s10e187/   https://curesyngap1.org/blog/ Issac's story, Transmitter reprint, Scramble 4 write up and JK on #Autism, #MustRead   https://curesyngap1.org/resources/webinars/ 119 - 112 Register for livestream of the conference, AAV from Allen Inst., dos en espanol, Missense, Unlock and Rare-X for ProMMiS.   https://curesyngap1.org/podcasts/syngap1-stories/  A gold mine have you listened to #38, the Virginie Pod, really must listen, she is our leader. https://www.linkedin.com/posts/graglia_syngap1stories-syngap1-syngap1storiesty-activity-7387203351907708928-liNL    CLINICAL TRIAL & GENETIC MEDICINE CORNER Example of Ultragenyx FAST Angelman follow on trial to look at other ages and genotypes, key message, never give up. https://www.linkedin.com/posts/cureangelman_the-global-aurora-study-will-enroll-approximately-activity-7389647402690957312-Bihi Congrats to Novartis on approval of the first Gene Therapy to Cure SMA! https://www.linkedin.com/posts/graglia_sma-fdaapproval-rarediseaseinnovation-activity-7398939783005347840-Ocd_ Remember Spinraza was approved in December 2019.   TODOS Sign up for Citizen Health: https://www.citizen.health/partners/srf USE YOUR ICD-10 F78.A1 #S10e185 https://www.youtube.com/watch?v=dale0NbxDpU Go to CURE SYNGAP1 Conference 2025 Atlanta: https://curesyngap1.org/events/conferences/cure-syngap1-conference-2025-hosted-by-srf/   SOCIAL MATTERS 4,468 LinkedIn.  https://www.linkedin.com/company/curesyngap1/  1,480 YouTube.  https://www.youtube.com/@CureSYNGAP1    11.2k Twitter https://twitter.com/cureSYNGAP1  45k Insta https://www.instagram.com/curesyngap1/    $CAMP stock is at $3.62 on 26 Nov. ‘25 https://www.google.com/finance/beta/quote/CAMP:NASDAQ Episode 190 of #Syngap10 #CureSYNGAP1

Use our code TALKIN10 for 10% off your next SeatGeek order*: https://seatgeek.onelink.me/RrnK/TALKIN10 Sponsored by SeatGeek. *Restrictions apply. Max $20 discountLooking for a refreshing citrusy kick this summer? Grab a Mountain Dew! Find out where at https://www.mountaindew.com/find-dewWhether you're just wanting to test an idea out, or you're getting serious about launching your own brand, it's never been easier to get started on https://shopify.com/talkinCheck out the newest JM channel, That's Cricket: https://www.youtube.com/ ⁨@thatscricketjm⁩   Coach Trev and Talkin' Jake break down the upcoming pitchers free agency, who will get the long term contracts, what Japanese pitcher Tatsuya Imai can get this off-season and more! 0:00: Intro5:15 Framber Valdez?7:30 Dylan Cease9:45 Ranger Suarez12:30 How long will these FA contracts be vs AAV?18:15Michael King, Brandon Woodruff21:45 Tastuya Imai27:45: Shane Bieber opts in35:00 Shota Imanaga opts out42:15 Zach Littel, Merril Kelly, Chris Bassitt45:00 Lucas Giolito46:00 Dustin May51:15 Relief pitching market53:45 Who has the most need for a closer?56:15 One reliever FA pick? Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

WWP NIGHT w/ the DETROIT RED WINGS (Nov. 15th vs. BUF) TICKETS:  https://www.gofevo.com/event/WingedWheelPodcast11-15 WWP NIGHT w/ the GRAND RAPIDS GRIFFINS TICKETS ON SALE NOW: https://griffinshockey.com/wwp The Detroit Red Wings preseason is over, and the kids are still here - is this the most optimistic preseason outlook in Winged Wheel Podcast history? (00:00) Tune in as we start by discussing Michael Brandsegg-Nygard's Detroit Red Wings & NHL-leading performance, how his game compares to Marco Kasper's, whether he could be a long-term solution for Todd McLellan next to Dylan Larkin & Lucas Raymond, & his chances of making the team (6:55). Next, what Justin Holl & Erik Gustafsson being waived mean for Axel Sandin Pellikka's roster chances, how his path compares to Moritz Seider & Simon Edvinsson's, if he's destined to be paired with Albert Johansson, & how the Grand Rapids Griffins AHL path could benefit him like it did Nate Danielson & other prospects (14:30). Finally, Emmitt Finnie's standout preseason & how he took the step past guys like Carter Mazur, Amadeus Lombardi, & Carter Bear, & what his roster chances are in McLellan and Steve Yzerman's eyes (28:20) before we give our full Detroit Red Wings Opening Night roster projections (40:10). After that, our Atlantic Division Preview, including Pastrnak's Boston Bruins, Dahlin's Buffalo Sabres, Raymond's Detroit Red Wings, Hutson's Montreal Canadiens, Tkachuk's Ottawa Senators, Kucherov's Tampa Bay Lightning, Barkov's Florida Panthers, and Matthews' Toronto Maple Leafs (52:30). We wrap up with a look at Jackson LaCombe & Luke Hughes' $9 million AAV contracts and what that means for Steve Yzerman as he looks to extend Simon Edvinsson (1:25:00). All of that & lots more before we take your questions and comments in our Overtime segment (1:30:00) - enjoy! Head over to wingedwheelpodcast.com to find all the ways to listen, how to support the show, and so much more! This episode is brought to you by Green Light Lending: gogreenlightlending.com #ad Support the Jamie Daniels Foundation through Wings Money on the Board: https://www.wingedwheelpodcast.com/wingsmotb